Response to beta interferon 1b among Saudi patients with multiple sclerosis.

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Remitting-relapsing MS (R-R MS) is the most common form, characterized by distinct attacks and periods of recovery.
• Beta interferons are a class of disease-modifying therapies used in MS management.

Purpose of the Study:

• To evaluate the efficacy and tolerability of subcutaneous beta interferon 1b (B1F1b) in Saudi patients diagnosed with R-R MS.
• To assess the impact of B1F1b on relapse rates, disability progression, and patient safety.

Main Methods:

• An open-label study conducted from March 1997 to December 2001, involving 32 Saudi patients with R-R MS.
• Patients received subcutaneous B1F1b (8 million IU) three times weekly.
• Outcome measures included annual relapse rate, proportion of relapse-free patients, time to first relapse, disability progression, tolerability, and safety.

Main Results:

• Analysis of 28 patients revealed a significant reduction in relapse rates.
• 32.5% of patients were relapse-free, and 37.5% experienced a reduction in relapse frequency.
• No patients showed progression in disability (P<0.0249); common adverse reactions included influenza-like symptoms (53.6%) and injection-site reactions (35.7%).

Conclusions:

• Subcutaneous B1F1b demonstrates efficacy in managing R-R MS, particularly in reducing relapse rates and potentially preventing disability.
• The treatment is well-tolerated among the studied Saudi patient population.
• Further long-term follow-up is recommended to fully ascertain the role of B1F1b in long-term disability prevention.